Neurokine Pharmaceuticals Inc.
OTC Bulletin Board : NEUKF

Neurokine Pharmaceuticals Inc.

December 09, 2010 09:01 ET

Neurokine Announces Completion of New Phase II Clinical Trial Plan for Treatment of Alzheimer's Type Memory Loss in CABG Patients

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 9, 2010) - Neurokine Pharmaceuticals Inc. (the "Company") (OTCBB:NEUKF) is pleased to announce the completion of its new clinical trials plan to test the effects of NK-001 in the treatment of Alzheimer's type memory loss in patients undergoing coronary artery bypass graft (CABG) surgery. The plan will be to carry out clinical trials in 50 patients following CABG surgery and to test these patients for up to 12 months following surgery for cognitive impairment (similar to Alzheimer's). The patients will be divided in 2 groups; 25 will receive NK-001 and 25 will receive placebo.

The clinical trials will be carried out in 4 to 6 sites with cardiosurgery and psychiatry expertise in Europe and expected to complete within 12 to 18 months. The company expects to finalize site selection and contract with its designated clinical investigation group in the next 4 to 6 weeks.

"We are extremely pleased with the completion of our new clinical trials plan. This is a milestone achievement for Neurokine as we look forward to the completion of our proposed Phase II trial plans," said Ahmad Doroudian, President and CEO of Neurokine.

About Neurokine

Neurokine Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Neurokine or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of Neurokine's products, the competitive environment within the industry, the ability of Neurokine to continue to expand its operations, the level of costs incurred in connection with Neurokine's expansion efforts, economic conditions in the industry and the financial strength of Neurokine's customers and suppliers. Neurokine does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information

  • Neurokine Pharmaceuticals Inc.
    Ahmad Doroudian, Ph.D.
    President and CEO
    (604) 805-7783